Dr. Patrice Rioux reports

THIOGENESIS THERAPEUTICS' MELAS ABSTRACT ACCEPTED FOR LATE-BREAKING NEWS PRESENTATION AT MITOCON 2026

An abstract outlining preliminary results from Thiogenesis Therapeutics Corp.'s phase 2 clinical trial of TTI-0102 for mitochondrial encephalopathy, lactic acidosis and strokelike episodes in the European Union has been accepted as late-breaking news for presentation at the Mitocon Conference 2026, which will take place in Pisa from Jan. 23 to Jan. 26, 2026.

The poster entitled, "Pharmacokinetics and Pharmacodynamics of TTI-0102 in MELAS," will be presented during the poster session on Jan. 23, and will summarize preliminary pharmacokinetic and pharmacodynamic findings from Thiogenesis's phase 2 MELAS study. The abstract was selected through Mitocon's late-breaking news review process by the conference's scientific committee.

The phase 2 MELAS clinical trial is a randomized, double-blind, placebo-controlled, multicentre study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and exploratory efficacy of oral TTI-0102 in patients with MELAS. As previously disclosed, interim results from the study demonstrated biological proof-of-concept and biomarker activity supporting TTI-0102's mechanism of action.

"Being selected for a late-breaking presentation at Mitocon underscores the scientific importance of the data generated in our phase 2 MELAS study," said Dr. Patrice Rioux, MD, PhD, chief executive officer and co-founder of Thiogenesis. "The pharmacokinetic and pharmacodynamic profile observed to date is consistent with TTI-0102's proposed mechanism of action and supports continued clinical development in MELAS and related mitochondrial disorders, including our upcoming phase 2a clinical trial in Leigh syndrome spectrum in the U.S."

About Thiogenesis Therapeutics Corp.

Thiogenesis is a clinical-stage biopharmaceutical company with operations based in San Diego, Calif. The company is publicly traded on the TSX Venture Exchange and in the United States on the OTCQX. Thiogenesis is developing sulphur-containing pro-drugs that act as precursors to previously approved thiol-active compounds, with the potential to treat serious pediatric diseases with unmet medical needs. Thiogenesis's lead product candidate, TTI-0102, has an active phase 2 clinical trial in mitochondrial encephalopathy, lactic acidosis and stroke, an investigational-new-drug-cleared phase 2a clinical trial planned in Leigh syndrome spectrum, a phase 2 clinical trial planned in pediatric metabolic dysfunction-associated steatohepatitis, and a phase 3 clinical trial planned in nephropathic cystinosis.

We seek Safe Harbor.